31 patents
Utility
Niclosamide Particles and Uses Thereof
28 Dec 23
The disclosure provides compositions and methods for use of compositions that include particles comprising at least 30% niclosamide by weight, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the particles have one or more of: (i) a mean bulk density (not tapped) of less than 0.40 g/cm3; 00 a mean tapped density of less than 0.55 g/cm 3 ; and/or (in) a specific surface area (SSA) of at least 3.6 m2/g.
Michael BALTEZOR, Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Aranza Barreda ABARCA
Filed: 8 Sep 21
Utility
Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles
23 Nov 23
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 13 Jul 23
Utility
b6qttdnmfxit88qokqlux77bp d2zyyle8ohb588iqp
16 Nov 23
Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, as are methods for their use, and methods for making such particles.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 18 Jul 23
Utility
cbay6itdhuu9syoq 8ejwlved043a3rv6g1le41qkb0quzdp4lix
11 May 23
Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.
Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
Filed: 8 Nov 22
Utility
eu1v0 fc0kch347f5z85383wh7xnsn6umwj7h00q
11 May 23
Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.
Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
Filed: 8 Nov 22
Utility
wsaw7i2wvhj6zpp a0qy
13 Apr 23
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 12 Oct 22
Utility
0d4agf6mrv5p4p38sn0bo
24 Nov 22
The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 14 Jul 22
Utility
pvhavhpykn1jbih98oh2yl
4 Aug 22
The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, methods for their use, and methods for making such particles.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 21 Jul 21
Utility
4kym338bduj0t7hjaq9aylm3fkezfs7i2bwligb5catqxcahmn1
31 Mar 22
Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles.
Gere S. DIZEREGA, Michael BALTEZOR, Charles DECEDUE, Sam CAMPBELL, Matthew MCCLOREY
Filed: 1 Oct 21
Utility
s790easqkkwj7nek26litsnhnm75roc6eqqcdud1d
17 Feb 22
Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents.
Gere S. DIZEREGA, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, Matthew MCCLOREY
Filed: 28 May 21
Utility
p01jzy55ebaljscfhp0w8gmiy72igs6fh3e1h0too1up2fjvvbzt
27 Jan 22
The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.
Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
Filed: 21 Jul 21
Utility
5qi6gj6cjx5mvqmo06xmbssu76b6jkr1ypigwzfi1myosd4avag
23 Dec 21
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g.
Michael BALTEZOR, Joseph FARTHING, Jake SITTENAUER, Jahna ESPINOSA, Samuel CAMPBELL, Matthew MCCLOREY, Julia K. FISCHER, Mark D. WILLIAMS, Gary E. CLAPP
Filed: 7 Sep 21
Utility
96zetn0gqo3olirqf10x38 46hq7zvp4j2dv5udoyn6v0z2l9ouv8
16 Dec 21
The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.
Mark WILLIAMS, Jacob SITTENAUER, Shelby CLARK, Joseph FARTHING, Michael BALTEZOR, Matthew MCCLOREY
Filed: 13 Aug 21
Utility
jfkmusbebst7fyf5w0mgc50g7yr98yyfuwexqcoz4w
26 Aug 21
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
Filed: 10 May 21
Utility
087ukf7 awivn65hl5szu
15 Jul 21
Disclosed are methods for the isolation of tumor-specific immune cells from subjects that have a malignant tumor and have received local administration of a composition comprising taxane particles to the malignant tumor, and use of such isolated immune cells in compositions for adoptive cell therapy and cancer vaccines.
Gere S. DIZEREGA, Holly MAULHARDT, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, William JOHNSTON, Matthew MCCLOREY, James VERCO
Filed: 12 Apr 19
Utility
a5i4ab3sr6dpm36cus5gvqc4ae4o6
6 Jan 21
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g.
Michael BALTEZOR, Joseph FARTHING, Jake SITTENAUER, Jahna ESPINOSA, Samuel CAMPBELL, Matthew MCCLOREY, Julia K. FISCHER, Mark D. WILLIAMS, Gary E. CLAPP
Filed: 16 Sep 20
Utility
t4frzobuvjb3ruhfiythu5w790kmjugzakw9qe460j
30 Dec 20
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g.
Michael BALTEZOR, Joseph FARTHING, Jake SITTENAUER, Jahna ESPINOSA, Samuel CAMPBELL, Matthew MCCLOREY, Julia K. FISCHER, Mark D. WILLIAMS, Gary E. CLAPP
Filed: 15 Sep 20
Utility
q84ffumat669 tvwk9vikasdx1q7nvcol
19 Aug 20
Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents.
Gere S. DIZEREGA, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, Matthew MCCLOREY
Filed: 29 Mar 20
Utility
niwb0eiyop l7dwutmi9oh2m1ox9nf59q889z06hd077wuvqwyqf77
5 Aug 20
Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
Filed: 2 Apr 20
Utility
jw77wb7nw5 zumerlhrsjzr6v2e29m4z8patodvaf9otjagjyeww
5 Aug 20
Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics.
Michael BALTEZOR, Matthew MCCLOREY, Joseph S. FARTHING, Mark WILLIAMS, Jacob SITTENAUER
Filed: 27 Sep 18